
|Articles|August 1, 2004
FDA panel rejects Allergan's Tazoral
National report - The benefits of Allergan's proposed oral psoriasis drug, Tazoral, do not outweigh possible risks of birth defects and bone loss, a U.S. Food and Drug Administration advisory panel has decided.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
3
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
4
Top 5 Articles of the Week: December 7-12
5


















